Aurealis Therapeutics
PrivateLast Round
VC Round
Nov 13, 2024
Total Funding Raised
$15.77M
Company Overview
Aurealis Therapeutics operates in Healthcare & Life Sciences and is based in Zug. Its latest recorded funding round was a VC Round in November 2024.
Aurealis Therapeutics is a clinical-stage synthetic biology company that develops multi-target cell and gene therapies for chronic wounds, cancers, and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aurealis Therapeutics Comparables
Compare Aurealis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ilya Pharma | 86% | |
| Azitra, Inc. | 77% | |
| PolarityBio, Inc. | 71% |
For institutional investors. Book with your work email.
Aurealis Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Nov 13, 2024 | ||||
| Series A | Mar 30, 2023 | ||||
| VC Round | Feb 12, 2019 | ||||
| Series A | Aug 25, 2017 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aurealis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Tesi | Series A |
| Lynx Financial | Series A |
| Finnvera | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 68% MoM.
- May 21, 2026
Monthly visitors increased 256% MoM, reaching 1.6K.
For institutional investors. Book with your work email.
Aurealis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Aurealis Therapeutics's valuation, stock price, and market status.
Is Aurealis Therapeutics a public or private company?
Aurealis Therapeutics is a private company.
What is the current stock price of Aurealis Therapeutics?
Aurealis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Aurealis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Aurealis Therapeutics worth (valuation)?
Valuation information for Aurealis Therapeutics is not publicly available.
Can I buy Aurealis Therapeutics stock?
Aurealis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Aurealis Therapeutics's last funding round?
Aurealis Therapeutics's most recent funding round was VC Round on November 13, 2024.
Who are the main investors in Aurealis Therapeutics?
Key investors in Aurealis Therapeutics include Tesi, Lynx Financial.
Will Aurealis Therapeutics IPO soon?
No public IPO plans have been announced for Aurealis Therapeutics.
How can I track Aurealis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Aurealis Therapeutics's shares on secondary markets.